Kintara Therapeutics, Inc. (KTRA) is a publicly traded company in the Unknown sector. Across all available filings, 8 corporate insiders have executed 27 transactions totaling $79.0K, demonstrating a bullish sentiment with $79.0K in net insider flow. The most recent transaction on Jun 1, 2023 involved a transaction of 59,800 shares valued at $0.
No significant insider buying has been recorded for KTRA in the recent period.
No significant insider selling has been recorded for KTRA in the recent period.
Based on recent SEC filings, insider sentiment for KTRA is bullish with an Insider Alignment Score of 100/100 and a net flow of $79.0K. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Kintara Therapeutics, Inc. (KTRA) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 8 insiders are actively trading KTRA stock, having executed 27 transactions in the past 90 days. The most active insider is Saiid Zarrabian (Executive), who has made 2 transactions totaling $31.4K.
Get notified when executives and directors at KTRA file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jun 1, 2023 | E. Hoffman Robert | Executive | Award | 59,800 | $N/A | $0 | |
| Jan 5, 2023 | M. Brown Dennis | Executive | Will Acquisition | 363 | $N/A | $0 | |
| Aug 1, 2022 | E. Hoffman Robert | Executive | Award | 400,145 | $N/A | $0 | |
| Aug 1, 2022 | M. Brown Dennis | Executive | Award | 240,087 | $N/A | $0 | |
| Aug 1, 2022 | Scott Praill Anthony | Executive | Award | 240,087 | $N/A | $0 | |
| Feb 15, 2022 | E. Hoffman Robert | Executive | Purchase | 55,000 | $0.47 | $25.9K | |
| Dec 8, 2021 | Scott Praill Anthony | Executive | Purchase | 28,700 | $0.68 | $19.5K | |
| Dec 7, 2021 | Zarrabian Saiid | Executive | Purchase | 38,109 | $0.64 | $24.4K | |
| Dec 6, 2021 | Zarrabian Saiid | Executive | Purchase | 11,891 | $0.59 | $7.0K | |
| Nov 22, 2021 | L. Johnson Laura | Executive | Purchase | 3,000 | $0.74 | $2.2K | |
| Apr 29, 2021 | Joseph Toth Robert Jr | Executive | Other | 3 | $N/A | $0 | |
| Apr 29, 2021 | Joseph Toth Robert Jr | Executive | Conversion | 325 | $N/A | $0 | |
| Apr 29, 2021 | Scott Praill Anthony | Executive | Conversion | 938 | $N/A | $0 | |
| Apr 29, 2021 | Scott Praill Anthony | Executive | Other | 8 | $N/A | $0 | |
| Apr 29, 2021 | M. Brown Dennis | Executive | Conversion | 750 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 7 | $79.0K | 100.0% |
Award(A) | 4 | $0 | 0.0% |
Will Acquisition(W) | 1 | $0 | 0.0% |
Other(J) | 12 | $0 | 0.0% |
Conversion(C) | 3 | $0 | 0.0% |
Insiders at Kintara Therapeutics, Inc. are accumulating shares at an accelerated pace. With 8 insiders making 27 transactions totaling $79.0K in purchases versus $0 in sales, the net buying activity of $79.0K signals strong executive confidence. Saiid Zarrabian (Executive) leads the buying activity with $31.4K in transactions across all time.